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Dose-dependent analgesia was produced by microinjection of ORG 2766 into the periaqueductal gray (PAG). 
This analgesia was found to be potent and long-lasting and occurred at doses which were equimolar to those 
necessary for morphine analgesia. The same doses failed to produce analgesia by the cerebroventricular route, 
suggesting that the PAG was the site of action of this effect. Naloxone failed to reduce the analgesia and mor- 
phine tolerance did not diminish the effect significantly. Additionally, ORG 2766 at concentrations up to 10 pM 
failed to inhibit binding of [3H]naloxone to brain opiate receptors in vitro. These results suggest a non-opiate 
mechanism of action and are discussed in terms of a proposed 0~-MSH or ACTH receptor. 
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1. Introduction 
The finding that adrenocorticotropin 
(ACTH) and ~-endorphin (~-END) coexist 
within arcuate nucleus and pituitary cells 
(Mains et al., 1977; Watson et al., 1978) and 
that both are derived from a larger neuronal 
glycoprotein of 31 000 daltons (Roberts and 
Herbert 1977; Nakanishi et al., 1979) raises 
new questions about the physiology of these 
substances. For example, assuming that these 
polypeptides are released together, it may be 
asked whether they exhibit antagonistic or 
cooperative effects. Several interactions 
between opiates and peptidds related to 
ACTH have been reported in recent years 
(Wiegant et al., 1977). ACTH1_24 binds 
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weakly to opiate receptors (Terenius et al., 
1975; Akil et al., 1980) and produces some 
naloxone reversable effects after central 
administration (Gispen et al., 1977). After 
peripheral administration, ACTH fragments 
and ~-MSH have sometimes antagonized the 
effects of opiates (Terenius, 1976; Zimmer- 
man and Krivoy, 1973; Gispen et al., 1975). 
It has also been suggested that ACTH plays a 
role in opiate withdrawal (Jaquet, 1978), in 
addition to a variety of other effects (Kastin 
et al., 1976; De Wied, 1977; Kastin et al., 
1979). 
Since ACTH-like peptides may share target 
cells with opiates, the present experiments 
were aimed at assessing the effects of an 
ACTH4-9 analog on a response with known 
opiate involvement, pain sensitivity. Micro- 
injections into the periaqueductal gray were 
used because this area is known to be critical 
to the action of opiates, rich in endogenous 
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opiates, and a terminal field for ACTH/~- 
END-containing neurons (Elde et al., 1976; 
Watson et al., 1977; Yaksh et al., 1976). We 
now report the induction of analgesia by the 
ACTH4-9 analog, ORG 2766. This analgesia is 
highly dose-dependent and occurs at doses 
which are the molar equivalent to those neces- 
sary for morphine analgesia. The analgesia is 
not  reversed by the opiate antagonist nalox- 
one, which may not  be surprising since ORG 
2766 was found not  to exhibit cross-tolerance 
with morphine and not  to bind to opiate 
receptors. 
2. Materials and methods 
2.1. Surgical procedures 
At least one week before testing, cannulae 
were implanted either in the lateral ventricle 
or the periaqueductal gray. Ventricular can- 
nulae were constructed from 22 ga thinwall 
stainless steel hypodermic tubing which were 
sharpened and beveled at the tips. A micro- 
syringe equipped with a 26 ga needle was used 
for injections. The needle extended 0.5 mm 
beyond the tip of the cannula. Ventricular 
injections were conducted over a period of 
one minute in a volume of 10 #l. 
Under sodium pentobarbitol anesthesia, 
ventricular cannulae were placed 1 mm poste- 
rior to bregma, 1.5 mm lateral to the midline, 
and 4.1 mm below the skull surface (lambda 
and bregma at same DV). Dental acrylic and 
stainless steel hooks were used to secure the 
cannula. 
Cannulae aimed at the periaqueductal gray 
were implanted using similar procedures. 
Cannulae were constructed from 24 ga thin- 
wall tubing. A 31 ga injection needle, which 
extended 2 mm beyond the tip of the can- 
nulae was used to avoid unnecessary tissue 
damage. Using the  stereotaxic atlas of De 
Groot (1959) the cannulae were implanted 
0.6 mm AP, 1.5 mm DV, and 0.5 mm LAT. 
Peptides were delivered in a 2 t~l volume. 
2.2. Analgesia testing 
Analgesia was measured by the tail-flick 
test of D'Amour and Smith (1941). The 
apparatus consisted of an adjustable heat 
source which could be directed onto the rat's 
tail. The application of power to the heat 
source started a solid state latency timer 
which in turn was stopped by withdrawal of 
the tail, allowing the light from the heat 
source to activate a photocell. A digital read- 
out, to tenths of a second, was thus provided 
for the latency to tail-withdrawal, which is 
the index of pain responsiveness. 
Ninety to 120 day old male Sprague- 
Dawley rats were used in all experiments. 
Eight animals with cannulae in the ventricles 
and eight with cannulae in the periaqueductal 
gray were tested once with 3, 9.5 and 30 #g 
of ORG 2766 (Met[O2] 4, D-Lys 8, Phe 9- 
ACTH4-9) and once with Ringer solution. All 
tests were separated by 48 h and the order of 
administration of the various doses was 
counterbalanced using a Latin Square Design. 
The central gray group was given an addi- 
tional test with 30 #g of ORG 2766, in com- 
bination with naloxone (2 mg/kg, adminis- 
tered subcutaneously). 
Before testing, the output  of the heat 
source was adjusted to obtain tail-withdrawal 
latencies between 2.5 and 4 sec. Tail-flick 
latencies were then measured every 2 min for 
a baseline period of 15 min. The peptide or 
control solution was then administered, and 
testing continued, at 2 min intervals, for a 
minimum of 20 min or until tail-flick laten- 
cies had returned to within 30% of their base- 
line values on three consecutive trials. In tests 
of naloxone, baselines were established over 5 
trials, followed by microinjection of 30 t~g 
ORG 2766. After analgesia was observed, 
judged by a 30% or higher increase in tail-flick 
latency for two tests, 2 mg/kg naloxone HC1 
in saline was injected subcutaneously. Tail- 
flick testing continued for a minimum of 20 
min and then ceased if latencies had returned 
to within 30% of baseline values. 
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2. 3. Induction of  morphine tolerance and its 
effect on analgesia produced by ORG 2766 
Ten animals underwent surgery as above. 
The seven which showed the greatest analgesia 
in response to a pretest with 30 pg of ORG 
2766 were subjected to further tests to deter- 
mine whether the analgesia exhibited cross- 
tolerance to morphine. After the initial test 
with the ACTH analog, the animals were given 
one test with 10 mg/kg morphine sulfate 
(intraperitoneally). Morphine tolerance was 
then induced by subcutaneous implantation 
of a morphine pellet (72 mg) under light ether 
anesthesia, followed three days later by the 
implantation of a second pellet. Four days 
later 10 mg/kg morphine was injected again 
and the resulting analgesic response was mea- 
sured. Forty-eight h later the effects of 30 t~g 
ORG 2766 was retested. Thus, the analgesic 
effects of both morphine and the ACTH4-9 
analog were observed before and after the 
induction of morphine tolerance. 
Testing for analgesia was as described above 
for ORG 2766. For morphine, testing ensued 
15 min after injection and 5 tests were made 
at 3 min intervals. 
2. 4. Histology 
After behavioral experiments were com- 
pleted animals were sacrificed by an overdose 
of sodium pentobarbitol. Brains were fixed by 
the perfusion of 10% formalin in saline 
through the heart. For ventricular placements 
the brain was cut with a scalpel and the 
ventricular system was checked for the pres- 
ence of dye (0.19% Evans blue, filtered) 
which was injected prior to sacrifice. Fifty 
#m frozen sections were obtained from brains 
with PAG implants and placements were 
determined with the aid of the stereotaxic 
atlas of De Groot (1959). 
2.5. Opiate binding assay 
The ability of ORG 2766 to inhibit the 
binding of [3H]naloxone to opiate receptors 
was carried out  using methods described by 
Akil et al. (1978). Briefly, whole brain minus 
cerebellum was homogenized in 10 vol of  ice 
cold 0.5 M Tris-HC1 buffer, pH 7.4 (0°C) and 
centrifuged at 35 000 × g for 30 min. After 
resuspension in the original volume, the prep- 
aration was incubated at room temperature 
for 30 min and spun again as before. The 
pellet was again resuspended in the original 
volume and the assay carried out with 0.5 ml 
aliquots of this preparation. Labelled nalox- 
one (3 nM) was added to the membrane prep- 
aration and incubated for 2 h at 0°C in the 
presence and absence of 10 nM to 10 t~M 
ORG 2766. The assay was conducted in 
triplicate. Samples were filtered by vacuum 
over Whatman GF/B filters. The filters were 
then counted by scintillation spectrometry. 
2.6. Materials 
[3H]Naloxone was purchased from New 
England Nuclear. Morphine Sulfate was pur- 
chased from Mallinkrodt. ORG 2766 was a 
gift from Organon. Naloxone HC1 was a gift 
from Endo Laboratories. 
3. Results 
3.1. Histology 
As shown in fig. 1, most of the cannulae 
were placed in the ventral and lateral portions 
of the central gray. The only animal who did 
not  show any analgesia after the drug, was 
also the only animal with a cannula clearly 
outside the central gray. This data may pro- 
vide some support for the conclusion that  the 
central gray was the site of action of ORG 
2766 in the present experiments. 
Dye was injected into the cannulae of ani- 
mals with ventricular implants. The dye was 
observed in the lateral ventricles of  all ani- 
mals. Minimal leakage of the drug up the side 
of the cannula was suggested by the lack of 
dye on the cortex in all but one animal. For 
the morphine-tolerant animals, most were 
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Fig. 1. Microinjection sites for ORG 2766. +, Dose- 
response study for one subject (histology lost for one 
subject). ©, Cross-tolerance study for one subject. 
again found to have cannulae in or very near 
the central gray. Evans blue was detected in 
the periaqueductal gray of all rats. Spreading 
was generally limited to a 1-3 mm region (see 
fig. 1). 
The effects of various doses of ORG 2766 
on analgesia were analyzed by methods 
described previously (Coy et al., 1978). An 
overall estimate containing both magnitude 
and duration of the drug was obtained by sub- 
tracting the animals' mean baseline score from 
each post-injection latency (all animals were 
included in the analysis). The area under the 
curve of the resulting time function was esti- 
mated using the approximation of  Simpson 
(c.f. Selby, 1964). This conservative method 
eliminates the inherent problems of analysis 
of variance with unequal cell sizes (number of 
tests per session). Moreover, it reduces the 
effects of the 10-sec ceiling on response 
latency, which would otherwise severely 
distort the within subjects variance. Thus, the 
transformed data for central gray injections 
were subjected to an 8 (subject)× 4 (dose) 
repeated measures analysis of variance. 
The results of increasing doses of ORG 
2766 (in PAG) on tail-flick latency are shown 
in fig. 2. One way analysis of variance con- 
firmed the obvious effectiveness of dose 
(F3,21 = 10.4, P < 0.0001). No effect of order 
of test was observed (F < 1). Post hoc analy- 
sis of individual doses was conducted using 
the Dunnet t  test. A significant effect of the 
30 pg dose compared to the control was ob- 
served (P < 0.01). The middle dose was not  
significant but the obvious effects seen in 3 
out  of 8 subjects strongly suggested that  it 
could indeed induce analgesia. 
Analysis of the effects of ventricular injec- 
tions of ORG 2766 revealed no significant 
effect of dose for data transformed as above 
(F3,21 = 1.29, P = 0.30). These results are 
illustrated in fig. 3. 
The transformed data of both experiments 
were combined in a 2 (groups)× 8 (sub- 
jects) × 4 (doses) analysis of variance. The 
large difference between injections into the 
central gray compared to injections into the 
lateral ventricle was confirmed by a signifi- 
cant difference between groups (F1,14 = 8.23, 
P--0.01) .  A main effect for dose was also 
obviously related to the strong effects of 
ORG 2766 after central gray injections 
( F 3 , 4 2  = 9.12, P < 0.0001). 
3.2. Naloxone effects 
No significant effect was observed for nal- 
oxone on analgesia of ORG 2766. Previous 
investigations with various known narcotics 
showed that  naloxone totally eliminated all 
signs of analgesia within ten min after injec- 
tion. In the present experiments the duration 
of analgesia was defined, as in a previous 
report (Walker et al., 1977a), as the time dur- 
ing response elevations were 30% greater than 
baseline. The duration of analgesia was not  
affected significantly by naloxone (T = 0.38, 
df  = 5). Duration of analgesia after naloxone 
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Fig. 2. Mean latency to tail withdrawal from radiant heat befo~:e and after microinjection of various doses of ORG 
2766 into the midbrain central gray. The peptide was dissolved in Ringer solution and injected in a 2 #l volume. 
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Fig. 3. Tail flick latency before and after lateral ventricular injection of  ORG 2766. No significant change in tail- 
flick latency was found for any dose. o, R; e, 3 ~g; D, 9.5 tlg; A, 30 #g. 
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Fig. 4. Mean tail flick latency before and after microinjection of 30 pg ORG 2766 or morphine in morphine 
tolerant or non-tolerant animals. Morphine dose 10.0 mg/kg i.p. Tolerance was induced by two successive 
implants of 72 mg morphine pellets. The significant decline of (P < 0.01) in the analgesic effects of a single dose 
of morphine was observed after exposure to the pellets for one week. No signficant effect of  morphine tolerance 
in ORG 2766-induced analgesia was observed. Ordina re: latency (sec); absicssa : time (min). 
was 30.5 + 7.3 (S.E.M.) min compared to 
33.3 + 8.4 (S.E.M.) min for 30 pg alone. How- 
ever, the small number of subjects make judge- 
ments of a small effect of naloxone impos- 
sible. 
3.3. Effects o f  morphine tolerance on anal- 
gesia produced by ORG 2766 
As illustrated in fig. 4, the tolerance regi- 
men produced a marked reduction in the anal- 
gesic potency of morphine but not  in the 
potency of ORG 2766. These data were 
reduced to give a measure of the degree of 
analgesia as adapted from Harris and Pierson 
(1964) and were subjected to a 7 (subjects) × 
2 (tolerance treatment) × 2 (drug) repeated 
measures analysis of variance. A significant 
degree of tolerance was revealed by a main 
effect (P < 0.01), and a significant interaction 
was observed (F1,6 = 4.4, P < 0.05), indicat- 
ing the significantly greater effect on mor- 
phine analgesia. Furthermore, individual anal- 
ysis of the effect of morphine before and 
after the tolerance regimen indicated a signifi- 
cant decline in the-effectiveness of morphine 
(P < 0.01), whereas the same morphine 
tolerant animals did not  exhibit a change in 
their response to ORG 2766 (P = 0.66). 
3.4. Opiate binding 
ORG 2766 was not  found to displace [3H]- 
naloxone from opiate receptors at concentra- 
tions up to 10 #M. Other doses from 1 nM to 
10 t~M were tested. Whereas binding in the 
presence of 1 t~M naloxone was only 30% of 
total binding, a small increase in binding (4%) 
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was observed with 10 ~M ORG 2766. Lower 
doses were equally ineffective. 
4. Discussion 
The results of the present experiments 
clearly show the effectiveness of the present 
doses of an ACTH analog in producing anal- 
gesia. Informal observations suggested that 
the ORG 2766 induced true analgesia since 
animals failed to show escape responses to 
strong pinches or to pin pricks. The results do 
not appear to be due to motoric deficits since 
the animals, while sometimes appearing 
sedate, often showed normal locomotor activ- 
ity during the period of profound analgesia. 
In fact, under the best circumstances analgesia 
was present in animals which would be diffi- 
cult or impossible to distinguish from un- 
treated rats on other grounds. The lack of 
effect of lateral ventricular injections, 
together with the histological data, strongly 
suggest that the periventricular gray is the site 
of action of the ACTH analog. 
While the doses used here are considerably 
higher than are necessary for changes in some 
behavioral situations, they are comparable to 
those usually needed for studies of pain 
sensitivity. For example, ORG 2766 is con- 
siderably more powerful than Met~enkephalin, 
in producing analgesia (Pert et al., 1976; 
Walker et al., 1977a, b). Using methods simi- 
lar to those of the present experiments, Pert 
et al. (1976) microinjected 120 ~g Met- 
enkephalin into the PAG and recorded tail- 
flick responses. Despite the 6 times higher 
dose (on a molar basis) of enkephalin, ORG 
2766 produces about 14 times the analgesia 
when calculated as area under the curve. In 
fact, when equated for molecular weight, the 
analgesic dose of ORG 2766 is approximately 
equivalent to that of morphine and many 
times lower than some partial agonists that 
are used clinically to relieve pain (Yaksh and 
Rudy, 1978). 
The discrepancy in doses is less surprising 
when one considers the case of the endor- 
phins. Like ACTH and ACTH analogs, opiate 
peptides have been found to produce changes 
in memory and attention at exceedingly low 
doses (Kastin et al., 1976; De Wied et al., 
1978). It has been suggested that these effects 
on learned behavior (maze performance, 
extinction and retention of avoidance 
behavior) are not mediated by opiate recep- 
tors since the effects can be seen with opiate- 
inactive analogs, such as the des-tyrosine- 
endorphins (De Wied et al., 1978). On the 
other hand, the analgesic effects of the endor- 
phins, which occur at higher doses, are antag- 
onized by naloxone, and thought to be opiate 
receptor mediated. Since these two effects 
(on learned behavior and pain sensitivity) 
occur at widely different doses and exhibit 
different pharmacological susceptibilities, it is 
likely that their underlying mechanisms are 
different as well. A similar situation may 
exist for ACTH. There may well exist two 
routes of action for ACTH, one that mediates 
the effects on learned behavior which is most 
readily seen at low doses, and a second that is 
reflected in its effects on pain sensitivity, and 
becomes apparent at higher doses. 
Since ACTH1-24 can induce some effects 
that are reversible by naloxone (Terenius, 
1976; Zimmerman et al., 1973; Gispen et al., 
1977) and since it binds, with low affinity, to 
opiate receptors, it was of particular interest 
to examine the role of the opiate receptor in 
the present phenomenon. The lack of effect 
of naloxone in the behavioral experiments, 
the failure of morphine tolerance to interfere 
with the analgesic response to ORG 2766, and 
the lack of its binding to opiate receptors in 
vitro strongly suggest that non-opiate mecha- 
nisms are responsible for the profound 
behavioral effects of this analog. One possibil- 
ity is that ORG 2766 interacts with a postu- 
lated ATCH or ~-MSH receptor. A particu- 
larly relevant finding in support of this view 
was that septal uptake of a [3H]ACTHI_9 ana- 
log is specifically reduced by other ACTH-like 
substances, notably the 1-24 fragment 
(Verhoef and Witter, 1977). 
Behavioral observations indicated several 
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other properties of ORG 2766 including its 
ability to produce straub tail and vigorous 
jumping. Similar effects have been reported 
for t3-END (Walker et al., 1977a) and 
ACTH1-24 (Jacquet, 1978; Walker et al., 
1980). Thus, at the level of the PAG, fi-END 
and a-MSH/ACTH-like peptides may produce 
a similar behavioral profile, suggesting parallel 
a c t i o n s -  presumably mediated via different 
receptor mechanisms. These data may thus 
extend the finding by Watson et al. (1978) 
and others (Pelletier et al., 1977; Mains et al., 
1977) of the coexistence of ACTH and fi-END 
within neurons, by suggesting that  ACTH and 
13-END have functional similarities as well. 
It is not  supposed that all effects of t3-END 
will be mimicked by ACTH-like substances 
since there are distinct groups of neurons con- 
taining only a-MSH (Watson and Akil, 1980). 
Moreover, exogenous administration of 
t3-END undoubtedly results in significant 
activation of opiate receptors that normally 
interact with enkephalin. However, the local 
activation of neurons in t3-END terminal 
regions by an ACTH analog and the concomi- 
tant analgesic effect suggests that physiologi- 
cally ~-END and ACTH may have effects that 
are functionally similar in nature. 
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